GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (FRA:2L9) » Definitions » Price-to-Owner-Earnings

Blueprint Medicines (FRA:2L9) Price-to-Owner-Earnings : (As of Jun. 18, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Blueprint Medicines Price-to-Owner-Earnings?

As of today (2024-06-18), Blueprint Medicines's share price is €97.92. Blueprint Medicines does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Blueprint Medicines's Price-to-Owner-Earnings or its related term are showing as below:

During the past 11 years, the highest Price-to-Owner-Earnings of Blueprint Medicines was 25.08. The lowest was 15.77. And the median was 19.92.


FRA:2L9's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.74
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-18), Blueprint Medicines's share price is €97.92. Blueprint Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-4.46. Therefore, Blueprint Medicines's PE Ratio for today is At Loss.

As of today (2024-06-18), Blueprint Medicines's share price is €97.92. Blueprint Medicines's EPS without NRI for the trailing twelve months (TTM) ended in was €-6.96. Therefore, Blueprint Medicines's PE Ratio without NRI for today is At Loss.

During the past 11 years, Blueprint Medicines's highest PE Ratio without NRI was 22.81. The lowest was 0.00. And the median was 17.57.


Blueprint Medicines Price-to-Owner-Earnings Historical Data

The historical data trend for Blueprint Medicines's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Price-to-Owner-Earnings Chart

Blueprint Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 22.09 - - -

Blueprint Medicines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Blueprint Medicines's Price-to-Owner-Earnings

For the Biotechnology subindustry, Blueprint Medicines's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blueprint Medicines's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's Price-to-Owner-Earnings falls into.



Blueprint Medicines Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Blueprint Medicines's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=97.92/-5.66
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Blueprint Medicines  (FRA:2L9) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Blueprint Medicines Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Blueprint Medicines (FRA:2L9) Business Description

Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Blueprint Medicines (FRA:2L9) Headlines

No Headlines